Convalescent Plasma in Hospitalized COVID-19 Patients
NCT05157165 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-07-21
Summary
The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.
Conditions
Interventions
- BIOLOGICAL
-
Convalescent plasma
Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
Sponsors & Collaborators
-
Azienda Socio Sanitaria Territoriale di Mantova
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
Convalescent Plasma in COVID-19 Elderly Patients
NCT04569188 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
NCT04397757 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19
NCT04388410 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19
NCT04425915 ·Status: COMPLETED ·Phase: PHASE3
-
Convalescent Plasma Trial in COVID -19 Patients
NCT04356534 ·Status: COMPLETED ·Phase: NA
-
Convalescent Plasma for COVID-19 Patients (CPCP)
NCT04521036 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Patients With COVID-19 With Convalescent Plasma
NCT04415086 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for the Treatment of COVID-19
NCT04389710 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma
NCT04340050 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
NCT04803370 ·Status: COMPLETED ·Phase: NA
-
Use of Convalescent Plasma for COVID-19
NCT04408040 ·Status: TERMINATED ·Phase: PHASE2
-
Convalescent Plasma in the Treatment of Covid-19
NCT04730401 ·Status: UNKNOWN ·Phase: PHASE2
-
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
NCT04332835 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
NCT04389944 ·Status: COMPLETED ·Phase: NA
-
Convalescent Plasma in the Treatment of Covid-19
NCT04600440 ·Status: UNKNOWN ·Phase: NA
-
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
NCT04420988 ·Status: NO_LONGER_AVAILABLE
-
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
NCT04354831 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for COVID-19
NCT04365439 ·Status: UNKNOWN ·Phase: NA
-
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
NCT04516811 ·Status: TERMINATED ·Phase: PHASE3
-
Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19
NCT04764747 ·Status: COMPLETED
-
Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients
NCT04530370 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340 ·Status: UNKNOWN ·Phase: PHASE1
-
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
NCT04428021 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt
NCT04816942 ·Status: COMPLETED ·Phase: PHASE3